Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multidrug-resistant tuberculosis detection, Latvia.

Girts Skenders1, Alicia M Fry, Inga Prokopovica

  • 1State Centre of Tuberculosis and Lung Diseases, Riga, Latvia.

Emerging Infectious Diseases
|October 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research overview-2025: integrating scientific progress to accelerate global tuberculosis elimination.

Frontiers in tuberculosis·2026
Same author

U.S. climate change policy must include vector-borne disease prevention.

Frontiers in public health·2026
Same author

Effects of age and birth cohort on influenza A virus subtype-specific hospitalization rates, United States 2010-2025.

The Journal of infectious diseases·2026
Same author

Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis.

Nature medicine·2026
Same author

Beyond emergency relief: The role of U.S. foreign health assistance amid growing displacement and climate change.

PLOS global public health·2025
Same author

Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial.

The Lancet. Infectious diseases·2025

A new line probe assay rapidly detects multidrug-resistant tuberculosis (MDR-TB) by identifying rpoB gene mutations. This assay significantly speeds up rifampin resistance diagnosis in Latvia, improving patient outcomes.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Molecular Diagnostics

Background:

  • Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health threat.
  • Rapid and accurate detection of MDR-TB is crucial for effective treatment and control.
  • Latvia faces an epidemic of MDR-TB, necessitating improved diagnostic capabilities.

Purpose of the Study:

  • To implement and evaluate the rpoB gene mutation line probe assay for MDR-TB detection in Latvia's national laboratory.
  • To assess the assay's performance in identifying rifampin resistance, a key indicator of MDR-TB.
  • To compare the turnaround time of the line probe assay with conventional methods.

Main Methods:

  • Introduction of the rpoB gene mutation line probe assay into the national laboratory workflow.

Related Experiment Videos

  • Testing patient samples for rifampin resistance using the line probe assay.
  • Comparison of diagnostic results and turnaround times with the BACTEC system.

    • Main Results:

    • The rpoB gene mutation line probe assay demonstrated high accuracy in detecting rifampin resistance.
    • Sensitivity was 91% and specificity was 96% for the line probe assay.
    • The assay provided results within 1 to 5 days, significantly faster than the 12 to 47 days required by BACTEC.

    Conclusions:

    • The successful introduction of the rpoB gene mutation line probe assay enhances MDR-TB detection capabilities in Latvia.
    • This rapid diagnostic method accelerates the identification of rifampin resistance, facilitating timely treatment initiation.
    • The assay represents a valuable tool for combating the MDR-TB epidemic in high-burden settings.